Employers grapple with GLP‑1 coverage

Employers and insurers are tightening coverage for popular weight-loss drugs as monthly costs pile up and many patients need the medicines long term. (nbcnews.com) At Jefferson, a Philadelphia-based nonprofit health system with 65,000 employees, chief executive Joseph Cacchione said prescription drugs now consume more of the company’s insurance spending than inpatient care. He said drug spending rose from about 14% of insurance costs a decade ago to 40% last year. (nbcnews.com) Cacchione said Jefferson’s insurance arm lost about $180 million in 2025, with roughly one-third of that tied to coverage of glucagon-like peptide-1 drugs such as Wegovy and Zepbound. Jefferson now requires workers to complete diet and lifestyle programs before the plan will cover those drugs for weight loss, and he said that change has already saved $20 million this year. (nbcnews.com) These drugs mimic a gut hormone that helps people feel full and can lower blood sugar, which is why they were first used for diabetes before booming as obesity treatments. The problem for employers is that the medicines are often taken for years, turning a one-time benefit decision into a recurring bill. (ajmc.com) (nbcnews.com) The price pressure is easy to see. NBC News reported Wegovy carries a monthly list price of $1,349 and Zepbound $1,086, while Blue Cross Blue Shield said the net cost to employer plans typically runs $617 to $766 per employee each month after discounts and rebates. (nbcnews.com) Coverage is uneven and, in some cases, shrinking. An April 15 report from NPR said plans are dropping coverage or adding restrictions, and GoodRx found that over the last year 12 million people lost coverage for Zepbound and another 12 million lost coverage for Wegovy. (wunc.org) (goodrx.com) Large employers have shown more willingness to cover the drugs, but with guardrails. Kaiser Family Foundation reported in October 2025 that bigger employers were increasing coverage for weight-loss use even as many considered scaling it back or strengthening requirements because of utilization and cost concerns. (kff.org 1) (kff.org 2) The same survey found family premiums in employer health plans reached $26,993 in 2025, up 6% from 2024, and workers paid $6,850 on average toward family coverage. In 2024, family premiums were already $25,572, which left employers little room to absorb another expensive drug class without changing benefits somewhere else. (kff.org 1) (kff.org 2) The medical case for staying on treatment is also getting clearer. A March 18 analysis summarized by The American Journal of Managed Care said Veterans Health Administration patients who stayed on glucagon-like peptide-1 therapy for about three years had an 18% lower risk of heart attack, stroke, or death than patients on sulfonylureas, but that advantage began fading within months after stopping. (ajmc.com) Six months after discontinuation, cardiovascular risk was 4% higher than for continuous users, the report said; after one year it was 14% higher, and by two years 22% higher, nearly wiping out the earlier benefit. That leaves employers, insurers and workers arguing over who should pay for drugs that can help quickly but may not stay effective once coverage ends. (ajmc.com)